Advanced Filters
noise

A, Concord N Clinical Trials

A listing of A, Concord N clinical trials actively recruiting patients volunteers.

Found 10,489 clinical trials

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis

This study is a randomized controlled phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with rheumatoid arthritis.

18 - 75 years of age All Phase 1
H Helle Pappot, Professor

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

This is an open-label phase I/II study evaluating the addition of ebastine to docetaxel in the treatment for metastatic castration resistant prostate cancer. Patients will be randomized in a 2:1 fashion to receive ebastine daily during and after treatment with a maximum of 10 courses of docetaxel. The primary endpoint …

18 years of age Male Phase 1/2

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.

18 years of age All Phase 1
K Kenneth Quick

Safety of a Single, Intravitreal Injection of 8.8M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 8.8 million (8.8M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (8.8M jCell) …

18 - 60 years of age All Phase 2

Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke

Large ischemic stroke is a severe subtype of acute ischemic stroke (AIS), often leading to malignant cerebral edema, elevated intracranial pressure, and poor functional outcomes. Despite early aggressive treatment, malignant cerebral edema remains a major determinant of prognosis, even in cases of successful recanalization. Preclinical studies suggest that a pharmacological …

18 years of age All Phase 3
J Jihui Hao, MD

A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor

This study is a Phase I, open-label, single-arm clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of GK01 in patients with advanced solid tumors.

18 - 70 years of age All Phase 1

PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm

Approximately 20% of young people experience self-harm behaviour in their lives. Self-harm can occur across different mental health disorders, and lead to negative outcomes and risk of suicide. Current treatments are long, costly and do not suit all young people, making it essential to research alternative treatments. Therapy combined with …

16 - 25 years of age All Phase 0
L Liqin Wu, Master

A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder

To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).

40 - 80 years of age All Phase 2
Y Yue DONG

A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors

This is a Phase I/II, open-label, preliminary study of safety, tolerability, pharmacokinetics, and efficacy. The study comprises three parts: a Dose Escalation cohort, a Dose Expansion cohort, and an Efficacy Expansion cohort. Dose Escalation cohort aims to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary efficacy of WJ22096 Tablets …

18 years of age All Phase 1/2

A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects

This phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-1180 after single- and multiple-ascending doses in healthy subjects.

18 - 55 years of age All Phase 1

Simplify language using AI